The BICO Group has been awarded 7 iF design awards for excellence in product designApril 20, 2022 12:00 pm
Handed to products that excel in their design and vision, the iF awards are voted on by a jury of 132 leading designers from across the globe with the goal to identify products which demonstrate the adoption of modern design trends and outstanding craftsmanship. For the third year in a row, BICO has taken home the award and extends its haul to 11 iF design awards in total, officially ranking within the top 10 companies in the healthcare/medical field.
Each business area was represented in the 7 awards that were handed out this year. BICO Biosciences was awarded an impressive 4 awards in total (Discover Echo 2, Cytena BPS 2), 2 awards were awarded to companies in BICO Bioautomation (Scienion, Cellenion) and the final award was picked up by BICO Bioprinting (Nanoscribe).
“We are thrilled to be recognized by the iF committee again this year. With this recognition BICO has entered the Top 100 companies for In House design and this is a great testament to the emphasis that we as a group are putting on design. We are focused on developing customer centric solutions that will support reducing the world’s organ shortages and speed up drug development.” says Markus Grip, Head of Brand & Design at BICO.
The full list of winners are as follows:
- C.NEST – modular high-throughput microbioreactor, CYTENA BPS
- S.NEST – High-throughput microbioreactor, CYTENA BPS
- Revolve – the world’s first hybrid microscope, Discover Echo
- Revolution – automated hybrid microscopy, Discover Echo
- Sphero One – Single spheroid and organoid sorter and dispenser, Cellenion
- S3 – Automated ultralow-volume liquid handler, Scienion
- Quantum X – High-precision 3D microfabrication printer, Nanoscribe
For further information, please contact:
Avijit Minocha, Head of Marketing, BICO
Phone (US): +1 (617) 637 5372
Founded in 2016, BICO (formerly CELLINK) is the leading bio convergence company in the world. By combining different technologies, such as robotics, artificial intelligence, computer science, and 3D bioprinting with biology, we enable our customers to improve people's health and lives for the better.
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO’s technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group’s instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com